ArticleAnnals of nuclear medicine2026
Association between technetium-99 m albumin scintigraphy-based severity of protein-losing enteropathy and patient characteristics and laboratory data.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic value of delayed-phase 99mTc-HSA scintigraphy and treatment outcomes in connective tissue disease-associated protein-losing enteropathy.Clinical rheumatology · 2026Article
- A Normalized Spot-Sample Estimation of α-1 Antitrypsin Clearance: The Search for a Simpler Test in Protein Losing Enteropathy.World journal of nuclear medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to demonstrate the differences in Technetium-99 m albumin scintigraphy findings for patients with protein-losing enteropathy (PLE) associated with their characteristics and laboratory data.
methodsEighteen patients with PLE were grouped into two based on two mechanisms: direct mucosal damage and failed lymph drainage. Scintigraphy images were divided based on the timing of acquisition: images obtained at 1, 2, 4, 6, and 24 h after starting the examination. The intensity of tracer uptake was graded as follows: 3 (marked uptake equal to or greater than the liver level), 2 (moderate uptake less than liver and greater than kidney levels), 1 (mild uptake less than kidney level), and 0 (negative). The grades at each timepoint for the two groups were compared using the Mann-Whitney U test. The associations between the grades and fecal alpha-1-antitrypsin and serum total protein concentrations were evaluated using Pearson correlation coefficients.
resultsOf 18 patients, 7 had PLE due to failed lymph drainage. The direct mucosal damage and failed lymph drainage groups had significantly different fecal alpha-1-antitrypsin concentrations [43.5 ± 29.6 (range 11-115) vs. 208.7 ± 66.0 (range 124-311), respectively; P < 0.001] and scintigraphy-based severity at 24 h [1.2 ± 0.8 (range 1-3) vs. 2.8 ± 0.4 (range 2-3), respectively; P = 0.007]. The fecal alpha-1-antitrypsin concentration was positively correlated with the scintigraphy-based severity at 6 h (r = 0.499, P = 0.049) and 24 h (r = 0.747, P = 0.002). However, the serum protein concentration was negatively correlated with the scintigraphy-based severity at 6 h (r = - 0.587, P = 0.017).
conclusionsThe scintigraphy-based severity at 6 and 24 h and the fecal alpha-1-antitrypsin concentrations were higher for patients with PLE due to failed lymph drainage mechanisms than for those with PLE due to direct mucosal damage. Scintigraphy can help localize the leakage point and determine disease severity to guide PLE management.
Indexed as
Identifiers
40982186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.